Sputnik V vaccine approved for use in Chile

Sputnik V vaccine approved for use in Chile

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian Sputnik V vaccine against coronavirus in the Republic of Chile.

Thus Sputnik V is now approved in 69 countries with total population exceeding 3.7 billion people – nearly half of the global population.

Real world data obtained during vaccination with Sputnik V in a number of countries (Argentina, San-Marino, Serbia, Hungary, Bahrain, Mexico, UAE, Philippines among others) demonstrate that Sputnik V is one of the safest and most effective vaccines against coronavirus. The Russian vaccine ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:

Sputnik V has been registered in a number of countries in Central and South America and is successfully used there to save lives. Authorization of the vaccine in Chile will help obtain access to one of the best vaccines against coronavirus. Sputnik V has demonstrated high efficacy and safety during the vaccination in many countries around the world. The vaccine creates a strong and durable immunity against COVID.

Sputnik V has a number of key advantages:

  • Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021.
  • The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
  • Sputnik V has pioneered the use of heterogeneous boosting (two different vectors for the two shots in a course of vaccination among COVID vaccines). This approach provides for immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
  • The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
  • There are no strong allergies caused by Sputnik V.
  • The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
  • The price of Sputnik V is less than $10 per shot, making it affordable around the world.
Text  |  Info: Enter some content to the textarea in the Text element, please.

Search engine for pharmaceutical industry resources

Type in a search phrase such as - gmp and get the search result

Don’t miss your daily PharmaProm.Ru news.
SUBSCRIBE free here

SUBSCRIBE
Loading…